- DURECT (NASDAQ:DRRX) will present a poster at The AASLD Liver Meeting Digital Experience (TLMdX) 2020, to be held virtually on November 13-16, 2020.
- Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients were released previously, showing an overall improvement from baseline in liver enzymes, liver stiffness, and serum lipid profiles.
- DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator.
- https://seekingalpha.com/news/3619762-durect-to-present-additional-phase-1b-durminus-928-data-in-nash-aasld-liver-meeting
Monday, October 5, 2020
Durect to present additional Phase 1b DUR-928 data in NASH at AASLD meeting
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.